US FDA accepts and grants priority review status to Verastem Oncology's NDA for avutometinib in combo with defactinib to ...
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval …